An exploratory study of a multi-species probiotic formulation and markers of health in a real-world oncological cohort in the time of covid.
- 2024-06-26
- Clinical Trial
- Inflammopharmacology 32(4)
- Michael Thomsen
- Ravichandra Vemuri
- Flavia Huygens
- Stephen Clarke
- Luis Vitetta
- PubMed: 38926298
- DOI: 10.1007/s10787-024-01503-1
- Moderate evidence
None of the participants had raised plasma-endotoxin levels from baseline to the first and subsequent treatment cycles for their cancers.
- Effect
- Neutral
- Effect size
- Small